IL
ILMN.US Illumina Inc
- Market cap
- USD 31.3B
- P/E
- 35.6x
- P/B
- 9.95x
- ROE
- 23.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ILMN.US undervalued?
Graham numberThe Graham number of Illumina Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Illumina Inc fundamental analysis
No fundamental analysis for Illumina Inc yet.
Illumina Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Illumina Inc
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific gene…
Full company profileIllumina Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Illumina Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.40B | 2.75B | 3.33B | 3.54B | 3.24B | 4.53B | 4.58B | 4.50B | 4.37B | 4.34B | 4.51B |
| Gross Profit | 1.67B | 1.83B | 2.30B | 2.47B | 2.20B | 3.15B | 2.97B | 2.74B | 2.86B | 2.89B | 3.09B |
| Operating Income | 587M | 606M | 883M | 985M | 393M | -123M | -4.18B | -1.07B | -833M | 864M | 1.01B |
| EBITDA | 735M | 762M | 1.06B | 1.17B | 580M | 128M | -3.79B | -1.07B | -725M | 1.46B | 1.22B |
| Net Income | 463M | 726M | 826M | 1.00B | 656M | 762M | -4.40B | -1.16B | -1.22B | 850M | 748M |
| EPS | 3.13 | 4.91 | 5.54 | 6.72 | 4.43 | 5.05 | -28 | -7.35 | -7.69 | 5.45 | 4.86 |
| Balance Sheet | |||||||||||
| Total Assets | 4.28B | 5.26B | 6.96B | 7.32B | 7.59B | 15.2B | 12.3B | 10.1B | 6.30B | 6.64B | 6.81B |
| Total Liabilities | 1.97B | 2.29B | 3.05B | 2.70B | 2.89B | 4.48B | 5.65B | 4.37B | 3.93B | 3.92B | 3.67B |
| Shareholders' Equity | 2.27B | 2.84B | 3.85B | 4.61B | 4.69B | 10.7B | 6.60B | 5.75B | 2.37B | 2.72B | 3.15B |
| Cash & Short-term Investments | 1.56B | 2.15B | 3.51B | 3.41B | 3.47B | 1.34B | 2.04B | 1.05B | 1.22B | 1.63B | 1.34B |
| Total Debt | 1.05B | 1.19B | 2.00B | 1.88B | 1.91B | 2.54B | 3.56B | 2.26B | 2.62B | 2.55B | 2.31B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 687M | 875M | 1.14B | 1.05B | 1.08B | 545M | 392M | 478M | 837M | 1.08B | 1.21B |
| Capital Expenditure | 271M | 312M | 296M | 209M | 189M | 208M | 286M | 195M | 128M | 148M | 159M |
| Free Cash Flow | 416M | 563M | 846M | 842M | 891M | 337M | 106M | 283M | 709M | 931M | 1.05B |
| Ratios | |||||||||||
| ROE | 20.4% | 25.5% | 21.5% | 21.7% | 14.0% | 7.1% | -66.7% | -20.2% | -51.5% | 31.2% | 23.8% |
| ROA | 10.8% | 13.8% | 11.9% | 13.7% | 8.6% | 5.0% | -35.9% | -11.5% | -19.4% | 12.8% | 11.0% |
| Net Profit Margin | 19.3% | 26.4% | 24.8% | 28.3% | 20.3% | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% | 16.6% |
| Debt to Equity | 0.46x | 0.42x | 0.52x | 0.41x | 0.41x | 0.24x | 0.54x | 0.39x | 1.10x | 0.94x | 0.74x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Illumina Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 937M | 5.97 | - |
| 2021 | USD 511M | 3.38 | 67.1% |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 735M | 4.93 | 89.0% |
| 2017 | USD 5.00M | 0.03 | 0.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1028:1000 on Jun 25, 2024.
Who owns Illumina Inc
- Insiders 0.94%
- Institutions 99.06%
- Public & others 0.00%
- Shares outstanding 151M
- Free float 151M
Top funds holding ILMN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 4.79M | 3.17% | +4.96% | Sep 2026 |
| Vanguard 500 Index Investor | 3.97M | 2.62% | 0.00% | Sep 2026 |
| Vanguard Small Cap Index | 3.40M | 2.25% | +2.75% | Sep 2026 |
| American Funds Growth Fd of Amer A | 2.18M | 1.44% | -20.45% | Sep 2026 |
| iShares Core S&P 500 ETF | 2.01M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 1.96M | 1.30% | 0.00% | Sep 2026 |
| American Funds American Balanced A | 1.95M | 1.29% | -44.17% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.89M | 1.25% | +99.31% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 1.84M | 1.22% | -0.25% | Oct 2026 |
| American Funds New Economy A | 1.80M | 1.19% | -32.81% | Sep 2026 |
| Vanguard Capital Opportunity Inv | 1.74M | 1.15% | -1.20% | Sep 2026 |
| JPMorgan Large Cap Growth I | 1.63M | 1.08% | +45.84% | Sep 2026 |
| Fidelity OTC | 1.41M | 0.93% | +323.91% | Aug 2026 |
| American Funds New Perspective A | 1.20M | 0.79% | -14.09% | Sep 2026 |
| iShares Biotechnology ETF | 1.17M | 0.78% | -0.32% | Oct 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 1.10M | 0.73% | +0.88% | Oct 2026 |
| Fidelity Contrafund | 1.10M | 0.73% | +14.95% | Sep 2026 |
| MFS Mid Cap Growth A | 1.02M | 0.68% | 0.00% | Sep 2026 |
| Invesco S&P 500® Equal Weight ETF | 962K | 0.64% | +0.17% | Oct 2026 |
| American Funds Fundamental Invs A | 932K | 0.62% | -6.77% | Sep 2026 |
Top institutions holding ILMN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 19.2M | 12.69% | +0.88% | Jun 2026 |
| Capital World Investors | 15.4M | 10.20% | -0.80% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 6.63M | 4.38% | -2.88% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.59M | 4.36% | -0.11% | Jun 2026 |
| State Street Corp | 6.51M | 4.30% | +1.21% | Jun 2026 |
| WCM Investment Management | 6.21M | 4.11% | +4.79% | Jun 2026 |
| FMR Inc | 4.52M | 2.99% | +192.43% | Jun 2026 |
| AQR Capital Management LLC | 3.54M | 2.34% | -10.97% | Jun 2026 |
| PRIMECAP Management Company | 3.49M | 2.31% | -0.67% | Sep 2026 |
| Geode Capital Management, LLC | 2.95M | 1.95% | -3.43% | Jun 2026 |
| Corvex Management LP | 2.83M | 1.87% | -26.09% | Jun 2026 |
| Jupiter Topco LLC | 2.04M | 1.35% | 0.00% | Jun 2026 |
| Amvescap Plc. | 1.99M | 1.32% | -24.96% | Jun 2026 |
| Loomis, Sayles & Company LP | 1.93M | 1.28% | -34.35% | Jun 2026 |
| Wellington Management Company LLP | 1.81M | 1.20% | +190.10% | Jun 2026 |
| Massachusetts Financial Services Company | 1.74M | 1.15% | +70.38% | Jun 2026 |
| Bank of New York Mellon Corp | 1.67M | 1.11% | +11.41% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.65M | 1.09% | -10.25% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 1.50M | 0.99% | -3.91% | Jun 2026 |
| Bank of America Corp | 1.46M | 0.96% | -4.04% | Jun 2026 |
Illumina Inc company profile
- Company name
- Illumina Inc
- Ticker
- ILMN.US
- Exchange
- USA Stocks
- Listed since
- Jul 28, 2000
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 8,600
- Fiscal year end
- December
- Address
- 5200 Illumina Way, San Diego, CA, United States, 92122
- Phone
- 858 202 4500
- Website
- illumina.com
About Illumina Inc
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Illumina Inc management
10- Mr. Jacob Thaysen Ph.D.CEO, President & Director · born 1975
- Mr. Ankur Dhingra CPAChief Financial Officer · born 1976
- Mr. Kevin Carl PegelsChief of Global Operations · born 1968
- Dr. Steven Barnard Ph.D.Chief Technology Officer · born 1961
- Mr. Scott EricksenVP & Chief Accounting Officer · born 1973
- Mr. Mark FieldChief Information Officer · born 1971
- Mr. Conor Noel McNamara C.F.A.VP of Investor Relations
- Ms. Julie Ann Coletti J.D.Chief Legal Officer · born 1968
- Mr. Jakob WedelChief Strategy & Corporate Development Officer · born 1972
- Ms. Patricia LeckmanSenior VP & Chief People Officer · born 1964